China SXT Pharmaceuticals, Inc. (SXTC) Free cash flow 2018–2026
China SXT Pharmaceuticals, Inc. (SXTC) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$4.0MFY2026 · since FY2018: $1.7M → -$4.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$4.0M | -70.9% |
| FY2025 | -$2.4M | — |
| FY2023 | -$141,689 | -174.6% |
| FY2022 | $189,991 | +113.1% |
| FY2021 | -$1.4M | -463.3% |
| FY2020 | $398,422 | +302.4% |
| FY2019 | -$196,825 | -111.3% |
| FY2018 | $1.7M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SXTC financial trends
SXTC RevenueSXTC Net incomeSXTC Net marginSXTC Gross profitSXTC Gross marginSXTC Operating incomeSXTC Operating marginSXTC Operating cash flowSXTC Capital expendituresSXTC Return on equitySXTC Stock buybacksSXTC Dividends paidSXTC Total assetsSXTC Total liabilitiesSXTC Shareholders’ equitySXTC overview →